The European Congress of Cardiology (ECC) 2025 recently concluded in MADRID, solidifying its position as a premier global event for cardiovascular specialists. The conference, held for the first time in the Spanish capital, convened thousands of experts, researchers, and healthcare professionals to discuss the latest scientific innovations, clinical updates, and professional insights in the field.

“It is indeed the first time that this congress is done in Madrid and to the best of my knowledge they are happy as attendance has been a record,” stated Luis Rodríguez Padial, president of the Spanish Society of Cardiology (SEC). He noted that the IFEMA venue provided ample space and comfort for attendees, while favorable weather conditions facilitated the smooth execution of all planned activities.

Beyond logistical considerations, the congress spotlighted meaningful advancements with the potential for a Direct impact on everyday clinical practice. One notable study, dubbed “reboot” and conducted across Spain and Italy, explored the use of beta blockers in post-heart attack patients. “It is a drug that we used to virtually used in all patients and here it has been seen that some patients may not benefit from their administration,” Rodríguez Padial explained.

The “reboot” study sparked considerable discussion, especially concerning its Findings in women, who appeared to derive even less benefit from beta blockers following a heart attack. “This is what has generated the most stir,” admitted the SEC president,anticipating that the study’s findings would significantly influence future clinical practices.

New and “old” findings

Another highlight of the ECC was the renewed interest in Digitoxina, a conventional medication that had previously faded into the background of modern cardiology. According to Rodríguez Padial, “the truth is that in a world in which there are so manny drugs that contribute so much to heart failure, it is peculiar that we have found that suddenly this can be useful in certain patients.” While its applications remain specific, digitoxin’s potential to improve outcomes for certain heart failure patients has piqued the interest of specialists.

The congress also showcased progress in treatments for myocardiopathies and in the use of defibrillators in carefully selected patient populations.

Moreover, the ECC featured the presentation of New clinical practice guides poised to reshape patient care. These included the first-ever guide dedicated to mental health in the context of cardiovascular disease,as well as a guide focused on pregnancy and cardiovascular pathology. «It is the first time that there is a guide on mental health and cardiovascular disease, which is a fairly relevant issue. Another on pregnancy and cardiovascular pathology, which is another key issue and from which there were no guides, » said Rodríguez Padial. Additional guides presented were updates to existing documents, providing evidence-based recommendations for managing various cardiovascular conditions.

Artificial intelligence (AI) emerged as a central theme in cardiovascular research and future clinical applications.The congress addressed AI’s potential in early detection and monitoring of patients with diverse cardiovascular diseases. Rodríguez Padial noted that the European Cardiology Society is planning a dedicated event on AI in the coming months, further emphasizing its growing role in clinical practice. «Now there are many knowledge and systems. Artificial intelligence I think will have an impact in the medium and long term, less in the short term, but obviously it will have a very important impact, » he stated.

An outstanding role of Spain

Spain played a prominent role in the research presented at the ECC in MADRID, not only through the “reboot” study but also with projects evaluating the effectiveness of heart failure units. Rodríguez Padial emphasized that these specialized units, recognized as a marker of quality care, “have an impact on the quality of life of patients and mortality,” demonstrating the importance of organized services in achieving positive clinical outcomes.

Cardiovascular diseases remain a leading cause of mortality in Europe. Consequently, Prevention remains a priority challenge, particularly given the continent’s diverse healthcare landscapes. “The European whole has a great heterogeneity in terms of the prevalence of cardiovascular diseases, such as, East countries have a much greater prevalence because they have more risk factors,” explained Rodríguez Padial.

In Spain, the National Cardiovascular Health Strategy, launched in 2022, is being progressively implemented. At the European level, the new strategy is expected to encompass All aspects of cardiovascular care: prevention, treatment, and care for complex patients. “The idea is that the European strategy addresses all the aspects that Spanish addresses, from the prevention, treatment and care of the most complex patients, which evidently must be sought to derive them to the most specialized center,” added the president of the SEC.

Heterogeneity among European health systems presents an additional rectum, but also provides opportunities to learn from best practices across different countries.

The lines that will mark cardiology

Among the key research areas shaping the future of cardiology, Rodríguez Padial highlighted Artificial intelligence, new drugs for lipid management, and advances in the treatment of cardiopathies and cardiac amyloidosis.

“There are drugs that prevent the amyloid being deposited,but there are developments to see,once the amyloid has been deposited in the heart,how to remove it,and there are studies in this regard,which would be an important step for these patients,” the specialist explained.

In addition to these advancements, the consolidation of Global cardiovascular health strategies will enable better guidance for future research and reinforce priority areas, such as prevention, care for high-risk patients, and optimization of treatments for chronic and acute diseases. According to Rodríguez Padial, the combination of clinical research, technological innovation, and the development of robust health policies will be crucial for improving outcomes and reducing cardiovascular mortality in Europe.

The European Congress of Cardiology 2025 in Madrid served as a pivotal meeting point, fostering collaboration between specialists and promoting the dissemination of scientific knowledge. The congress underscored that European cardiology is progressing towards more personalized, evidence-based treatments supported by cutting-edge technology, solidifying Madrid’s role as a global hub for cardiovascular innovation.